目的 探討利妥昔單抗注射液聯(lián)合多柔比星脂質(zhì)體治療復(fù)發(fā)難治性非霍奇金淋巴瘤的臨床療效和不良反應(yīng)。方法 選取2014年1月—2015年1月滄州市中心醫(yī)院收治的復(fù)發(fā)難治性非霍奇金淋巴瘤患者60例為研究對(duì)象，所有患者隨機(jī)分為對(duì)照組和治療組，每組各30例。對(duì)照組靜脈滴注鹽酸多柔比星脂質(zhì)體注射液，20 mg/m²，1次/2周。治療組在對(duì)照組的基礎(chǔ)上靜脈滴注利妥昔單抗注射液375 mg/m²，1次/周。兩組患者均連續(xù)治療6周。觀察兩組的臨床療效，比較兩組的無進(jìn)展生存期（PFS）、總生存期（OS）和患者Karnofsky（KPS）評(píng)分。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為36.67%、66.67%，疾病控制率分別為56.67%、80.00%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，治療組PFS、OS和KPS評(píng)分均顯著高于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療組發(fā)生白細(xì)胞計(jì)數(shù)降低、貧血的例數(shù)顯著低于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 利妥昔單抗注射液聯(lián)合多柔比星脂質(zhì)體治療復(fù)發(fā)難治性非霍奇金淋巴瘤具有較好的臨床療效，可延長患者生存時(shí)間，改善生活質(zhì)量，安全性較好，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of Rituximab Injection combined with Doxorubicin Hydrochloride Liposome Injection in treatment of relapsed or refractory non-Hodgkin's lymphoma. Methods Patients (60 cases) with cerebral infarction in Cangzhou Central Hospital from January 2014 to January 2015 were randomly divided into control and treatment groups, and each group had 30 cases. Patients in the control group were iv administered with Doxorubicin Hydrochloride Liposome Injection, 20 mg/m², once weekly. Patients in the treatment group were iv administered with Rituximab Injection on the basis of the control group, 375 mg/m², once every two weeks. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacies were evaluated, and PFS, OS, KPS scores in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 36.67% and 66.67%, respectively, and the disease control rates in the control and treatment groups were 56.67% and 80.00%, respectively, and there was difference between two groups (P < 0.05). After treatment, PFS, OS, KPS scores in the treatment group were significantly higher than those in the control group, and there was difference between two groups (P < 0.05). The number of white blood cell count and anemia in the treatment group were significantly lower than those in the control group, and there was difference between two groups (P < 0.05). Conclusion Rituximab Injection combined with Doxorubicin Hydrochloride Liposome Injection has clinical curative effect in treatment of relapsed or refractory non-Hodgkin's lymphoma, can prolong survival time and improve quality of life, with good safety, which has a certain clinical application value.